Les anticholinestérasiques en soins de longue durée : analyse des pratiques actuelles à partir d'une étude observationnelle francoquébécoise
- 31 August 2006
- journal article
- research article
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 27 (8) , 588-594
- https://doi.org/10.1016/j.revmed.2006.04.012
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Impact économique de la démenceLa Presse Médicale, 2005
- A Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home SettingJournal of the American Geriatrics Society, 2001
- Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trialBMJ, 2000
- A 5-month, randomized, placebo-controlled trial of galantamine in ADNeurology, 2000
- Galantamine in ADNeurology, 2000
- The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1Dementia and Geriatric Cognitive Disorders, 1999
- Defining Meaningful Change in Alzheimer's Disease Trials: The Donepezil ExperienceJournal of Geriatric Psychiatry and Neurology, 1999
- Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsawBMJ, 1999
- Donepezil Improves Cognition and Global Function in Alzheimer DiseaseA 15-Week, Double-blind, Placebo-Controlled StudyArchives of internal medicine (1960), 1998
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998